A J Templeton - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

A J Templeton

Showing results (1-10 of 16) with videos related to

Pageof 2

Sort By:

Praxis|October 26, 2005

[Swollen leg with blisters]Ph Rafeiner, A J Templeton, H J Vonesch

Journal of Veterinary Internal Medicine|November 1, 1993

Evidence for genetic involvement in feline dilated cardiomyopathyD F Lawler, A J Templeton, K L Monti

Clinical Oncology (Royal College of Radiologists (Great Britain))|February 4, 2018

Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysisR Barua, A J Templeton, B Seruga, et al.

Clinica Chimica Acta; International Journal of Clinical Chemistry|February 28, 1985

Plasma glutathione S-transferase measurements by radioimmunoassay: a sensitive index of hepatocellular damage in manG J Beckett, E H Dyson, B J Chapman, et al.

Prostate Cancer and Prostatic Diseases|September 28, 2016

Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancerG Sonpavde, G R Pond, A J Templeton, et al.

Current Surgery|January 1, 1990

Chitosan: evaluation of a new hemostatic agentG M Kind, S D Bines, E D Staren, et al.

Cancer Treatment Reviews|February 2, 2016

Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapiesA Srikanthan, F Vera-Badillo, J Ethier, et al.

Clinical Oncology (Royal College of Radiologists (Great Britain))|November 7, 2015

Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical TrialsH Y AlHashem, M Al-Mubarak, F E Vera-Badillo, et al.

European Journal of Cancer (Oxford, England : 1990)|March 18, 2014

Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancerM G McNamara, A J Templeton, M Maganti, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2014

Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid useD Lorente, J Mateo, A J Templeton, et al.

Pageof 2

Search research articles

Showing results (1-10 of 16) with videos related to

Sort By:

Pageof 2

Praxis|October 26, 2005

[Swollen leg with blisters]Ph Rafeiner, A J Templeton, H J Vonesch

Journal of Veterinary Internal Medicine|November 1, 1993

Evidence for genetic involvement in feline dilated cardiomyopathyD F Lawler, A J Templeton, K L Monti

Clinical Oncology (Royal College of Radiologists (Great Britain))|February 4, 2018

Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysisR Barua, A J Templeton, B Seruga, et al.

Clinica Chimica Acta; International Journal of Clinical Chemistry|February 28, 1985

Plasma glutathione S-transferase measurements by radioimmunoassay: a sensitive index of hepatocellular damage in manG J Beckett, E H Dyson, B J Chapman, et al.

Prostate Cancer and Prostatic Diseases|September 28, 2016

Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancerG Sonpavde, G R Pond, A J Templeton, et al.

Current Surgery|January 1, 1990

Chitosan: evaluation of a new hemostatic agentG M Kind, S D Bines, E D Staren, et al.

Cancer Treatment Reviews|February 2, 2016

Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapiesA Srikanthan, F Vera-Badillo, J Ethier, et al.

Clinical Oncology (Royal College of Radiologists (Great Britain))|November 7, 2015

Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical TrialsH Y AlHashem, M Al-Mubarak, F E Vera-Badillo, et al.

European Journal of Cancer (Oxford, England : 1990)|March 18, 2014

Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancerM G McNamara, A J Templeton, M Maganti, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2014

Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid useD Lorente, J Mateo, A J Templeton, et al.

Pageof 2